8-K
filed August 8, 2023, 7:59 PM ET
ticker TRDA
CIK 0001689375
earnings
confidence high
sentiment positive
materiality 0.75
Entrada Q2 cash $376.8M; on track to dose first participant in ENTR-601-44 Phase 1 in Sept 2023
Entrada Therapeutics, Inc.
2023-Q2 EPS reported
-$0.99
revenue$43,430,000
- Cash, cash equivalents and marketable securities of $376.8M as of June 30, 2023, up from $188.7M at year-end 2022; cash runway extended through 2025.
- Collaboration revenue of $18.2M in Q2 2023 (none in prior year); net loss $25.9M vs $23.2M.
- Received MHRA and REC authorization for Phase 1 trial of ENTR-601-44 in healthy volunteers in UK; first dosing expected in September 2023 with data in H2 2024.
- IND for ENTR-601-44 on clinical hold with FDA; update expected in Q4 2023.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Entrada Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $25.9 million for the second quarter of 2023.
- Period
- second quarter 2023
- Net income
- Net loss was $25.9 million for the second quarter of 2023
- Result
- reported results
Exact text from the filing
Net loss was $25.9 million for the second quarter of 2023, compared to a net loss of $23.2 million for the same period in 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Entrada Therapeutics, Inc. reported second quarter 2023, quarter ended June 30, 2023 results: revenue 18.2 million, net income -25.9 million.
- Period
- second quarter 2023, quarter ended June 30, 2023
- Revenue
- 18.2 million
- Net income
- -25.9 million
- Result
- reported results
Exact text from the filing
Collaboration revenue was $18.2 million for the second quarter of 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.